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Abstract
Background: In recent years, preoperative volume reduction of locally advanced breast cancers,
resulting in higher rates of breast-conserving surgery (BCS), has become increasingly important
also in postmenopausal women. Clinical interest has come to center on the third-generation
nonsteroidal aromatase inhibitors (AIs), including letrozole, for such neoadjuvant endocrine
treatment. This usually lasts 3–4 months and has been extended to up to 12 months, but optimal
treatment duration has not been fully established.
Methods: This study was designed as a multicenter, open-label, single-arm, exploratory phase IIb/
III clinical trial of letrozole 2.5 mg, one tablet daily, for 4–8 months. The primary objective was to
investigate the effect of neoadjuvant treatment duration on tumor regression and BCS eligibility to
identify optimal treatment duration. Tumor regression (by clinical examination, mammography, and
ultrasound), shift towards BCS eligibility, and safety assessments were the main outcome measures.
Standard parametric and nonparametric descriptive statistics were performed.
Results: Letrozole treatment was received by 32 of the enrolled 33 postmenopausal women
(median (range): 67.0 (56–85) years) with unilateral, initially BCS-ineligible primary breast cancer
(clinical stage ≥ T2, N0, M0). Letrozole treatment duration in the modified intent-to-treat (ITT;
required 4 months' letrozole treatment) analysis population (29 patients) was 4 months in 14
patients and > 4 months in 15 patients. The respective per-protocol (PP) subgroup sizes were 14
and 11. The majority of partial or complete responses were observed at 4 months, though some
beneficial responses occurred during prolonged letrozole treatment. Compared with baseline,
median tumor size in the ITT population was reduced by 62.5% at Month 4 and by 70.0% at final
study visit (Individual End). Similarly, in the PP population, respective reductions were 64.0% and
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67.0%. Whereas initially all patients were mastectomy candidates, letrozole treatment enabled BCS
(lumpectomy) in 22 ITT (75.9%) and 18 PP (72.0%) patients.
Conclusion: Over half of patients become BCS-eligible within 4 months of preoperative letrozole
treatment. While prolonged treatment for up to 8 months can result in further tumor volume
reduction in some patients, there is no clear optimum for treatment duration. Letrozole has a
favorable overall safety and tolerability profile.
Trial registration: ClinicalTrials.gov identifier NCT00535418.
Background
Until more recently, the conventional treatment of estro-
gen/progesterone receptor (ER/PgR) positive breast cancer
in elderly postmenopausal women consisted primarily of
surgery, followed by adjuvant endocrine or sequential
chemo-endocrine therapy, and radiotherapy, depending
on type of surgery (mastectomy or breast conservation),
tumor volume and lymph node involvement [1]. In prac-
tice, regardless of disease stage, elderly patients still more
frequently undergo mastectomy and receive less aggres-
sive adjuvant treatment because of toxicity concerns;
moreover they are also more likely to be given exclusively
endocrine therapy if their tumors are hormone-sensitive
[2].
Volume reduction of locally advanced breast cancers and
the resulting rise in the rate of breast-conserving opera-
tions have come to play a progressively more important
role also in elderly patients. Recent reports increasingly
support the concept of primary endocrine therapy as an
option for postmenopausal women with locally advanced
receptor-positive breast cancer [3-6].
In the 1990s, the selective estrogen receptor modulator
tamoxifen, until recently the gold standard in the adju-
vant and metastatic treatment settings, was shown also to
be effective as neoadjuvant endocrine therapy [7-9]. More
recently, however, the focus of clinical interest has shifted
to the third-generation nonsteroidal aromatase inhibitors
(AIs) [10] such as letrozole and anastrozole as these drugs
appear to produce at least comparable (anastrozole) or
better overall response rates and permit more conservative
subsequent surgery than tamoxifen [11-14].
Early neoadjuvant letrozole studies, in which postmeno-
pausal patients were usually treated for 3 or 4 months
[15,3,16], suggested that prolongation of AI treatment
might further improve tumor shrinkage and down-stag-
ing, thus facilitating breast-conserving surgery (BCS). We
therefore undertook the present study to investigate the
potential benefits of extended neoadjuvant letrozole ther-
apy with a view also to identifying optimal treatment
duration.
Methods
Study design and setting
Conducted at six breast cancer treatment centers in Ger-
many, this study was a multicenter, open-label, single-
arm, exploratory phase IIb/III clinical trial of pre-opera-
tive letrozole treatment in postmenopausal women aged
55 years and older with untreated primary breast cancer.
The neoadjuvant endocrine treatment regimen consisted
of one 2.5 mg letrozole tablet daily for 4 to 8 months. The
trial was approved in advance by, inter alia, the Ethics
Committee of the Faculty of Medicine of the University of
Tübingen and carried out in compliance with Good Clin-
ical Practice guidelines (the 1964 Declaration of Helsinki
as last amended in 1996; Directive 91/507/EEC; and US
21 Code of Federal Regulations, parts 50 and 56).
The primary study objective was to investigate the effect of
the duration of treatment with letrozole 2.5 mg on tumor
regression and on patient eligibility for breast-conserving
surgery (BCS). Additional objectives included assessment
of the safety and tolerability of the letrozole treatment reg-
imen and subsequent procedures. All patients exposed to
one or more doses of letrozole were included in the anal-
ysis of safety and tolerability (Safety).
The trial was originally designed to include ≥ 30 patients
who, after showing clinical complete response (CR) or
partial response (PR) at Month 4 (120 days, range
105–135 days), would continue letrozole treatment up to
Month 8 (240 days, range 225–255 days).
Patients
Inclusion criteria
Patients were required to be postmenopausal females (no
spontaneous menses for ≥ 1 year; LH and FSH levels > 40
IU/L; or bilateral oophorectomy prior to breast cancer
diagnosis) older than 55 years with primary invasive
breast cancer, to give prior written informed consent and
to be able to comply with the study protocol. Tumors had
to be (a) of clinical stage T2 (only if ineligible for breast-
conserving surgery (BCS)), T3, T4a, T4b, or T4c, in con-
junction with N0 and M0 (no palpable axillary lymph
nodes; no metastases); (b) measurable by clinical palpa-
tion, mammography (MG) and ultrasound (US); and (c)BMC Cancer 2008, 8:62 http://www.biomedcentral.com/1471-2407/8/62
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histologically confirmed by core needle biopsy and posi-
tive for estrogen receptors (ER) and/or progesterone
receptors (PgR) as defined by core biopsy immunohisto-
chemistry with > 30% positive malignant epithelial cells.
Additional requirements included adequate bone marrow
function (white blood cell count (WBC) ≥ 3.5 × 109/L;
platelet count ≥ 100.0 × 109/L) and hemoglobin levels (>
11.0 g/dL), adequate renal function (creatinine < 120
μmol/L) and hepatic function (bilirubin < 25 μmol/L,
aspartate transaminase (AST) < 60 IU/L), and a life expect-
ancy of at least six months.
Exclusion criteria
Patients were not included in the trial if they were eligible
for breast-conserving surgery or had a history or diagnosis
of (a) prior treatment with AIs or antiestrogens; (b)
uncontrolled endocrine disorders such as diabetes, con-
firmed hypothyroidism or hyperthyroidism, Cushing's
syndrome, or Addison's disease (treated or untreated); (c)
unstable angina, uncontrolled cardiac disease; (d) bilat-
eral breast tumors; (e) inflammatory breast cancer or dis-
tant metastasis; or (f) concurrent malignant disease (with
the exception of cone-biopsied cervical carcinoma in situ,
adequately treated basal or squamous cell carcinoma of
the skin, or other curable cancers (e.g. Hodgkin's or non-
Hodgkin's lymphomas), provided five recurrence-free
years had elapsed since completion of therapy).
Also excluded from participation were patients with
multifocal tumors (more than one lesion within any one
quadrant of the breast) and patients receiving concomi-
tant anti-cancer treatments such as chemotherapy, immu-
notherapy/biological response modifiers (BRMs),
endocrine therapy (including steroids), bisphosphonate
therapy (except for osteoporosis, in which case it was
acceptable as concomitant therapy) and radiotherapy.
Hormone replacement therapy (HRT) did not constitute
an exclusion criterion provided it was discontinued at
least two weeks before entry into the study. Concomitant
treatment with steroids (e.g. glucocorticoids for indica-
tions other than cancer) was permitted only as aerosol
treatment for obstructive airways disease or as intraarticu-
lar steroid injections for the treatment of inflammation.
Patients who had received other investigational drugs
within the preceding 30 days or were concomitantly tak-
ing other investigational drugs were also excluded from
study participation.
Treatments
Study drug
Letrozole (code name CGS 20267, trade name Femara®),
2.5 mg tablets) from a single batch (No. S05400) was sup-
plied by Novartis Pharma GmbH, Nuremberg, Germany
to the main investigator at each of the participating cent-
ers. Drug supplies were for use in this study only and had
to be stored securely and in accordance with the storage
conditions specified on the study drug labels.
Dose regimen
Patients took one oral dose (one 2.5 mg tablet) of letro-
zole a day for a period of up to 8 months. Study medica-
tion accounting was carried out by study center, but the
study did not provide for a determination of compliance
rates. Surgery was scheduled 4 months (105–135 days)
from the date of first study treatment. In late-onset
responders, surgery was postponed until Month 8
(225–255 days) if necessary and feasible to ensure there
would be no interval between the last day of study treat-
ment, and surgery. There was no reference treatment as
this was an uncontrolled trial with only one treatment
arm. Concomitant medication was permitted within the
confines of the above exclusion criteria.
Tumor response assessments and study visits
Clinical tumor measurements and mammography and
breast ultrasound examinations were performed at base-
line, at monthly post-baseline visits – the visits at Month
4 (after 105–135 days) and Month 8 (after 225–255 days
of letrozole treatment) being of central importance to the
study – and at the patient's last study visit (Individual
End) to determine clinical tumor response. CR was
defined as the disappearance of all known disease, as
determined by two observations obtained no less than 4
weeks apart. Similarly, PR was considered to have
occurred if total tumor size decreased by at least 50% in
the absence of any progression or new lesions. Decreases
by < 50% and increases by < 25% were considered to rep-
resent no change (NC), while increases ≥ 25% or appear-
ance of new lesions (were classed as progressive disease
(PD).
Statistical considerations and analysis
Sample size
No formal sample size estimation was performed for this
exploratory trial. The targeted sample size was 30 patients
who would continue letrozole treatment beyond Month
4. It was estimated that about 50 patients would need to
be recruited, because 20% (10 patients) would experience
treatment failure (with subsequent surgery) and another
20% (10 patients) would undergo surgery at Month 4 for
other reasons.
Statistical analysis
Data analysis was performed by IMEREM GmbH, Nurem-
berg, Germany, on behalf of, and in close cooperation
with, Novartis Pharma GmbH and in accordance with the
study protocol, the statistical analysis plan as well as spon-
sor and IMEREM standard operating procedures. All sta-
tistical analysis was conducted at a descriptive level usingBMC Cancer 2008, 8:62 http://www.biomedcentral.com/1471-2407/8/62
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Base SAS® software (SAS Institute Inc., Cary, NC, U.S.A.),
Version 8.2 for Windows®. No confirmatory hypothesis
testing was planned or performed. In the case of statistical
comparisons, results were interpreted in a descriptive and
exploratory manner. Standard descriptive statistics were
used, which comprised both parametric (including confi-
dence intervals) and nonparametric methods.
Data presentation and analysis of baseline disease characteristics
Data were summarized using contingency tables for qual-
itative variables (n, %) and summary statistics for quanti-
tative variables (mean and standard deviation; median
and range).
Efficacy Analysis
First, tumor regression with treatment duration of at least
4 months was confirmed by calculating the response rates
based on clinical tumor assessment, MG, and breast US.
Second, regression analysis to determine the effect of
treatment duration on tumor regression was performed
for patients who were not considered treatment failures
after 4 months of letrozole. The effects of baseline tumor
size, nodal involvement, and age on treatment response
were evaluated descriptively.
Safety analysis
This was based mainly on the types and frequencies of
adverse events (AEs), which were classified by body sys-
tem and preferred term and summarized as the number
and percentage of patients experiencing at least one such
AE. Additional information (e.g. severity or relationship
to study drug) was presented in by-patient tabular listings.
Analysis populations
In addition to, and in modification of, the protocol-
defined Safety and ITT populations, further analysis sub-
populations were defined post hoc, as provided for in the
protocol for this exploratory study. Thus data analysis was
performed for the following three subsets of patients.
Safety population
This subset included all patients treated with at least one
dose of study medication.
Intent-to-treat (ITT) population
In view of the primary objective of the trial, this efficacy
population was modified a posteriori to exclude both
untreated patients and those who took study medication
for less than 4 months (< 105 days), i.e. the minimum
treatment duration for clinically sound assessment of
letrozole efficacy with respect to tumor shrinkage. Tumor
assessment by at least one study assessment method (clin-
ical assessment, breast US, or MG) after 4 months
(105–135 days) of letrozole treatment was an additional
ITT requirement.
Per-protocol (PP) population
Defined post hoc, the PP efficacy population was
obtained by excluding from the ITT subset all patients
with major protocol violations, these being defined as (a)
an interval of more than 30 days between the last dose of
letrozole and breast surgery; (b) the patient's refusal to
undergo surgery; (c) deviation from clinically relevant
selection criteria; and (d) any treatment with prohibited
medication.
Efficacy and safety assessments
The main outcome measures were tumor regression (as
assessed by clinical examination, MG, and bidimensional
breast US, and evaluated according to the WHO criteria
[17]), shift towards BCS eligibility, and safety assess-
ments. Any concomitant medication, coexisting diseases,
and adverse events were coded using WHO dictionaries or
a similar thesaurus before entry into the database.
Efficacy assessments included clinical assessment, MG,
and breast US by the investigator. For each methodology,
response status was based on WHO criteria. The results of
tumor assessment by the investigators were used for statis-
tical analysis.
Safety assessments consisted of monitoring and record-
ing all adverse events, serious adverse events (with their
severity and, if any, relationship to the study drug) and
assessments of vital signs (systolic and diastolic blood
pressure, and pulse rate), including body weight/body
mass index (BMI). Adverse events (AEs) were recorded in
the Case Report Form, stating duration, severity (Grade
1–4 (mild, moderate, severe or life-threatening)), rela-
tionship to the study drug (suspected/not suspected), and
any action(s) taken. Serious AEs were recorded on a sepa-
rate, purpose-designed form.
Results
Patients
Disposition, baseline demographics, and disease characteristics
The study enrolled 33 postmenopausal Caucasian women
at 6 breast cancer centers in Germany between June 15,
2000 and July 23, 2002 (last completion). The number of
patients per center ranged between 2 (3 centers) and 16 (1
center). Of those enrolled, 32 patients were exposed to at
least one dose of letrozole, 3 discontinued treatment, and
29 completed letrozole treatment. The one patient who
was not exposed was excluded from all analyses. Slow
recruitment ultimately resulted in discontinuation of
recruitment and premature termination of the trial.
Table 1 summarizes the baseline demographic data for the
32 patients who were evaluable for safety analysis.BMC Cancer 2008, 8:62 http://www.biomedcentral.com/1471-2407/8/62
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All patients were postmenopausal as defined by the inclu-
sion criteria. Overall, the sample composition closely
matched the targeted population. The disease characteris-
tics are summarized in Table 2. The typical patient pre-
sented with breast cancer in the upper outer quadrant, the
tumor being moderately differentiated and predomi-
nantly of ductal histology. All 32 patients exposed to
letrozole had primary tumors that tested positive for
estrogen and/or progesterone receptors (ER+/PgR+). One
patient was positive for progesterone receptor only. The
proposed surgery at baseline was mastectomy for all
patients (information missing for one patient).
Patient exposure
The duration of letrozole treatment (N = 32) ranged from
2 to 8 months. The main treatment duration categories
with 3 or more patients were 4, 5, and 8 months, which
comprised 14, 5, and 7 (43.8, 15.6, and 21.9%), respec-
tively, i.e. 81.3% in total, of the 32 Safety-evaluable
patients. Median total duration of treatment was about
130 days (4.3 months) with a range from 56 to 258 days
(1.9–8.5 months), as detailed in Table 3). Of the 15
patients treated for more than four months, 7 (i.e. 21.9%
of the Safety population, or 24.1 and 28% of the ITT and
PP populations, respectively (cf. Table 4)) received letro-
zole for about 8 months.
Analysis populations
The sizes of the three analysis populations in this study are
given in Table 4, together with the sizes of subgroups by
treatment duration.
The final number of patients enrolled was considered suf-
ficient to allow descriptive analysis of the safety (32 safety-
evaluable patients) and efficacy of letrozole and to esti-
mate the potential benefits of preoperative letrozole as a
neoadjuvant treatment in postmenopausal primary breast
cancer.
Effect of treatment duration on tumor regression
Tumor response
The WHO tumor response results at Month 4, Month 8
and Individual End of treatment (final examination) are
summarized for the ITT and PP populations in Table 5.
Comparison of tumor assessments
Overall, clinical tumor assessment at Individual End
yielded the highest response rates (complete or partial
response: 21/29 (72.4%) ITT patients; 18/25 (72.0%) PP
patients). MG at Individual End yielded the least favora-
ble findings (no complete, only partial responses in 7/29
(24.1%) ITT patients and 5/25 (20.0%) PP patients).
Results for breast US at Individual End were somewhat
less favorable compared with the clinical tumor assess-
ments (complete or partial response in 18/29 (62.1%) ITT
patients and 15/25 (60.0%) PP patients).
Treatment duration and tumor response
Of the 5 ITT patients without change in clinical tumor
assessment at Month 4, 2 showed partial response and 1
complete response at Month 8. None of the patients with
unchanged MG findings at Month 4 showed a more favo-
rable response at Month 8, but 1 patient whose breast US
was unchanged at Month 4 had partial response at Month
8. In the PP population, responses were observed in 9 of
24 (37.5%) evaluable patients at Month 4 without addi-
tional treatment, and in another 9 patients after extended
treatment, 6 patients having had partial or complete
response at Month 4. Thus, partial or complete response
was already achieved in 15 patients (62.5%) after 4
months of letrozole treatment.
Reduction in tumor size
Compared with baseline, median tumor size in the ITT
population was reduced by 62.5% at Month 4 and by
70.0% at Individual End. In the PP population, median
tumor size was similarly reduced by 64.0% (Month 4) and
67.0% (Individual End).
Table 1: Demographic data at study entry for the Safety 
population of 32 postmenopausal Caucasian women with 
untreated primary breast cancer
Mean ± SD Median (Range)
Age (yrs) 68.4 ± 7.2 67.0 (56–85)
Weight (kg) 72.6 ± 16.4 68.5 (49–120)
BMI (kg/m2) 27.2 ± 5.4 26.0 (20.1–44.6)
Table 2: Diagnosis and extent of cancer in the Safety population 
(N = 32) at study entry
No. of patients % of Safety
population
Clinical tumor categories
T2* 23 71.9
T3 5 15.6
T4a 1 3.1
T4b 3 9.4
Primary tumor histology
Ductal 19 59.4
Invasive lobular/variant 8/1 25.0/3.1
Other/missing 3/1 9.4/3.1
Tumor grade
Well/moderately/poorly 
differentiated
3/16/2 9.4/50.0/6.3
Missing 11 34.4
Positive receptor status
Estrogen/progesterone/either 31/25/32 96.9/78.1/
100.0
* only if ineligible for breast-conserving surgeryBMC Cancer 2008, 8:62 http://www.biomedcentral.com/1471-2407/8/62
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Relationship between treatment duration and tumor response
Table 6 shows the results for the ITT and PP populations
of the threefold statistical analysis of clinical tumor assess-
ment, MG, and breast US as calculated by Pearson corre-
lation (percent change in tumor size from baseline to
Individual End vs. days on letrozole treatment), Spear-
man correlation (tumor response categories 1 (CR) to 4
(PD)) at Individual End vs. days on letrozole treatment),
and multiple regression analysis (percent change in tumor
size as criterion, and days on treatment, age, and tumor
size at baseline as predictors).
As regards clinical tumor assessment, there was a moder-
ate correlation between the clinically assessed tumor
response at Individual End and treatment duration in that
tumor size decreased and calculated tumor response
improved with increasing treatment duration.
The correlations between treatment duration and decrease
in tumor size were slightly higher in the PP population
than in the ITT population, indicating that letrozole had a
favorable effect on tumor shrinkage when treatment was
administered as planned, i.e. for a sufficiently long period.
The variables examined in the multiple regression analy-
ses failed to explain a significant portion of the variance in
the percent change in tumor size observed between base-
line and Individual End of letrozole treatment.
For clinical tumor assessment, there was a moderate Pear-
son correlation between treatment duration and change
in tumor size from baseline (ITT: r = -0.3146; PP: r = -
0.4003), and a substantial Spearman correlation between
treatment duration and tumor response (ITT: r = -0.3839;
PP: r = -0.5092). The respective MG correlations were
modest or negligible (Pearson, ITT: r = -0.2396; PP: r = -
0.2956; Spearman, ITT: r = -0.1037; PP: r = +0.0409), and
the breast US correlations were low to moderate (Pearson,
ITT: r = -0.2099; PP: r = -0.3188; Spearman, ITT: r = -
0.4111; PP: r = -0.3371), with substantial negative corre-
lations indicating that longer treatment duration was
associated with a more favorable response. Multiple
regression analysis revealed no consistent and statistically
relevant influence of age and tumor size at baseline.
Tumor staging, lymph nodes, and metastases
Changes in pathological tumor staging are given in Table
7 for all patients exposed to study drug, including those
treated less than 4 months. Overall, the changes were
observed after a median treatment duration of 4.3
months. The data demonstrate that a shift to less severe T-
stages occurred in the course of treatment. Moreover, at
the final assessment, no or only very few lymph nodes
were affected in the majority of patients and none of the
30/32 patients examined had metastases (data not
shown).
Subsequent breast surgery
The lumpectomy and mastectomy frequencies in the
Safety and Efficacy populations are summarized in Table
8. All patients treated with letrozole for 4 months under-
went surgery no later than 30 days after taking the last
dose of study drug. Of the patients treated for more than
4 months, the majority (73.3%) of the ITT population and
all (100%) PP patients had breast surgery within 30 days
of the last dose of study medication. Whereas initially all
patients were candidates for mastectomy, letrozole treat-
ment enabled BCS (lumpectomy) in 22/29 (75.9%) ITT
patients and 18/25 (72.0%) PP patients.
Safety and tolerability
Adverse events
Of the 82 adverse events (AEs; MedDRA low level terms,
no multiple counts) reported in 27/32 (84.4%) Safety-
evaluable patients, only 1 AE was both severe and serious
(colon cancer, nos (not otherwise specified)). One other
serious adverse event (SAE) that occurred in a different
patient (upper limb fracture nos) was moderate but
required hospitalization. Neither SAE was suspected to be
related to letrozole. None of the non-serious AEs led to
discontinuation, temporary interruption of treatment
Table 3: Overall treatment duration in the Safety population (N = 32)
Months of treatment
< 4 4 > 4 Total
No. of patients 3 14 15 32
Median duration (range) (in days) 65 (56–94) 121 (105–130) 214 (138–258) 129.5 (56–258)
Mean duration ± SD (in days) 71.7 ± 19.9 120.1 ± 7.1 200.9 ± 46.4 153.5 ± 57.1
Table 4: Number of patients (and percentage of subgroup total) 
in the Safety and Efficacy (ITT and PP) analysis populations, 
grouped by treatment duration
Treatment duration (months)
Population < 4 4 > 4 Total
Safety 3 (9.4%) 14 (43.8%) 15 (46.9%) 32
Intent-to-treat (ITT) n.a. 14 (48.3%) 15 (51.7%) 29
Per-protocol (PP) n.a. 14 (56.0%) 11 (44.0%) 25
n.a. = not applicable as this analysis population, by definition, 
contained no patients treated for less than 4 monthsBMC Cancer 2008, 8:62 http://www.biomedcentral.com/1471-2407/8/62
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with study drug, or dose adjustment. No deaths were
reported in this study.
Other safety assessments
No laboratory assessments were performed. Vital signs
(diastolic and systolic blood pressure, pulse rate, and
body weight/body mass index), some abnormal at base-
line, generally improved rather than deteriorated over the
course of the study.
Discussion
The third-generation AIs are increasingly challenging
tamoxifen, hitherto the gold standard in the endocrine
treatment of estrogen-responsive postmenopausal breast
cancer, in both the neoadjuvant and adjuvant settings
[18]. For instance, superior efficacy of letrozole over
tamoxifen as neoadjuvant treatment for postmenopausal
patients with ER+/PgR+ breast cancer has been demon-
strated by Eiermann et al. [3]. More recently, Paepke et al.
Table 5: WHO tumor response status (n, %) in the ITT and PP populations at Months 4 and 8 and Individual End of letrozole 
treatment
Intent-to-treat population, N = 29 Per-protocol population, N = 25
Month 4 Month 8 Individual End Month 4 Month 8 Individual End
Tumor response Clinical tumor assessment Clinical tumor assessment
complete response 1 (3.5%) 1 (3.5%) 2 (6.9%) 1 (4.0%) 1 (4.0%) 2 (8.0%)
partial response 15 (51.7%) 6 (20.7%) 19 (65.5%) 14 (56.0%) 3 (12.0%) 16 (64.0%)
no change (stable disease) 5 (17.2%) 1 (3.5%) 4 (13.8%) 3 (12.0%) 0 (0.0%) 3 (12.0%)
progressive disease 2 (6.9%) 0 (0.0%) 3 (10.3%) 2 (8.0%) 0 (0.0%) 3 (12.0%)
Missing observations 6 (20.7%) 21 (72.4%) 1 (3.5%) 5 (20.0%) 21 (84.0%) 1 (4.0%)
Tumor response Mammography Mammography
complete response 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
partial response 7 (24.1%) 2 (6.9%) 7 (24.1%) 5 (20.0%) 1 (4.0%) 5 (20.0%)
no change (stable disease) 11 (37.9%) 1 (3.5%) 13 (44.8%) 10 (40.0%) 0 (0.0%) 11 (44.0%)
progressive disease 1 (3.5%) 0 (0.0%) 1 (3.5%) 1 (4.0%) 0 (0.0%) 1 (4.0%)
Missing observations 10 (34.5%) 26 (89.7%) 8 (27.6%) 9 (36.0%) 24 (96.0%) 8 (32.0%)
Tumor response Breast ultrasound Breast ultrasound
complete response 1 (3.5%) 1 (3.5%) 2 (6.9%) 1 (4.0%) 1 (4.0%) 2 (8.0%)
partial response 13 (44.8%) 5 (17.2%) 16 (55.2%) 11 (44.0%) 2 (8.0%) 13 (52.0%)
no change (stable disease) 6 (20.7%) 1 (3.5%) 8 (27.6%) 5 (20.0%) 1 (4.0%) 7 (28.0%)
progressive disease 1 (3.5%) 0 (0.0%) 1 (3.5%) 1 (4.0%) 0 (0.0%) 1 (4.0%)
Missing observations 8 (27.6%) 22 (75.9%) 2 (6.9%) 7 (28.0%) 21 (84.0%) 2 (8.0%)
Table 6: Relationship between treatment duration and tumor response
Clinical assessment Mammography Breast ultrasound
ITT (n = 28) PP (n = 24) ITT (n = 21) PP (n = 17) ITT (n = 27) PP (n = 23)
Pearson correlation r = -0.3146 r = -0.4003 r = -0.2396 r = -0.2956 r = -0.2099 r = -0.3188
p = .1030 p = .0526 p = .2955 p = .2494 p = .2934 p = .1382
Spearman correlation r = -0.3839 r = -0.5092 r = -0.1037 r = +0.0409 r = -0.4111 r = -0.3371
p = .0437 p = .0110 p = .6548 p = .8761 p = .0331 p = .1158
Multiple regression analysis F = 1.96 F = 1.66 F = 0.87 F = 0.60 F = 0.73 F = 1.05
p = 0.1471 p = 0.2070 p = 0.4748 p = 0.6278 p = 0.5465 p = 0.3928
R2 = 0.1967 R2 = 0.1996 R2 = 0.1334 R2 = 0.1212 R2 = 0.0866 R2 = 0.1424
R2* = 0.0963 R2* = 0.0795 R2* = -0.0195 R2* = -0.0816 R2* = -0.0326 R2* = 0.0070
* adjusted.
Threefold statistical analysis performed for clinical tumor assessment, MG, and breast US included: a) Pearson correlation of percent change in 
tumor size from baseline to Individual End vs. days on letrozole treatment; b) Spearman correlation of tumor response categories (1 = CR to 4 = 
PD) at Individual End vs. days on letrozole treatment; and c) multiple regression analysis of percent change in tumor size as criterion vs. days on 
treatment, age, and tumor size at baseline as predictors (3 degrees of freedom). Deviations in ITT and PP population sizes from 29 and 25, 
respectively, were due to non-analyzable patients.BMC Cancer 2008, 8:62 http://www.biomedcentral.com/1471-2407/8/62
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[19] and Renshaw et al. [20] published abstracts of their
findings regarding the optimal duration of neoadjuvant
treatment with letrozole. To date, no other study has
addressed this issue. The current paper is the first full
report of the data previously presented in brief by Paepke
and coworkers.
The present study was conducted as a single-arm explora-
tory trial primarily to investigate the effect of treatment
duration with letrozole 2.5 mg/day on tumor regression
and eligibility for breast-conserving surgery (BCS) in post-
menopausal primary hormone-responsive breast cancer,
also with a view to identifying optimum duration of treat-
ment. The trial was stopped prematurely due to slow
patient recruitment at the participating centers. Therefore,
instead of the planned total number of 50 patients, the
number of Safety-evaluable patients recruited was 32,
with 29 and 25 patients being available for the ITT and PP
analyses, respectively, and 15 ITT and 11 PP patients
instead of the expected 30 patients receiving more than
four months' letrozole treatment. In deviation from the
study protocol, letrozole treatment was prolonged in four
patients who showed no change as defined by the WHO
criteria (i.e. had stable disease) at the Month 4 assessment.
In these cases, the investigators' clinical judgment and
expectation that patients would benefit from further letro-
zole treatment was given priority over strict adherence to
the protocol schedule, with the result that three of the four
patients benefited from prolonged letrozole therapy.
Overall, however, the down-sizing of the study and the
minor deviations from the study protocol were consid-
ered acceptable in view of the exploratory nature of the
trial.
The definition of the intent-to-treat (ITT) population used
in this study was a stricter modification of the common
definition in that it excluded 3 patients who received less
than 4 months (105 days) of letrozole treatment. How-
ever, to enable analysis in accordance with the primary
study objective, this restriction was considered necessary
since a clinically valid assessment of letrozole efficacy in
terms of tumor shrinkage required a minimum of 4
months' treatment. An additional ITT requirement was a
final examination using at least one of the three study
assessment methods, i.e. clinical palpation, MG, or breast
US.
Under the conditions of our study, the majority of
patients responded to letrozole treatment by Month 4,
with respective overall ITT and PP response rates of 55.2%
(CR 3.5%, PR 51.7%) and 60% (CR 4.0%, PR 56.0%) for
clinical palpation. Of the 15 ITT and 11 PP patients
treated until Month 8, 7 (1 CR, 6 PR) and 4 (1 CR, 3 PR)
patients, respectively, showed response as determined by
clinical palpation, yielding overall response rates of
24.2% (CR 3.5%, PR 20.7%) and 16.0% (CR 4.0%, PR
12.0%) relative to the respective overall population sizes
of 29 and 25, and thus indicating benefit from prolonged
letrozole treatment. At Individual End, reflecting general
therapeutic benefit from 4 to 8 months' neoadjuvant oral
letrozole, respective overall clinical palpation response
rates in ITT and PP patients were 72.4% (CR 6.9%, PR
65.5%) and 72.0% (CR 8.0%, PR 64.0%), suggesting
incremental benefit from letrozole treatment of more
than 4 months' duration.
For all assessment times, overall response rates were gen-
erally similar for clinical palpation and breast US but
markedly less favorable for MG. The concordance
between assessment methods, or lack thereof, awaits fur-
ther investigation.
Table 7: Tumor staging before and after letrozole treatment 
(Safety population (N = 32), number and percentage of patients)
Clinical stage Baseline Individual End
T1a -- 1 (3.1%)
T1b -- 1 (3.1%)
T1c -- 7 (21.9%)
T2 23 (71.9%) 19 (59.4%)
T3 5 (15.6%) --
T4a 1 (3.1%) --
T4b 3 (9.4%) --
Missing -- 4 (12.5%)
Table 8: Lumpectomy and mastectomy frequencies in the Safety and Efficacy populations after study treatment (number of patients 
and percentage of respective analysis subset)
Safety ITT PP
N = 32 = 4 months (N = 14) > 4 months (N = 15) = 4 months (N = 14) > 4 months (N = 11)
n (%) n (%) n (%) n (%) n (%)
Lumpectomy 22 (68.8%) 10 (71.4%) 12 (80.0%) 10 (71.4%) 8 (72.7%)
Mastectomy 9 (28.1%) 4 (28.6%) 3 (20.0%) 4 (28.6%) 3 (27.3%)
Missing data 1 (3.1%) -- -- -- --
Total 32 (100.0%) 14 (100.0%) 15 (100.0%) 14 (100.0%) 11 (100.0%)BMC Cancer 2008, 8:62 http://www.biomedcentral.com/1471-2407/8/62
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Our finding that median tumor size was reduced by 70%
and 67.0% at Individual End vs. 62.5% and 64.0% at
Month 4 in the ITT and PP populations, respectively,
lends further support to the conclusion that prolongation
of letrozole treatment can be associated with incremental
therapeutic benefit.
Similarly, correlation analyses of treatment duration ver-
sus change in tumor size from baseline (Pearson) and
tumor response (Spearman) as assessed by clinical palpa-
tion yielded moderate and substantial correlations,
respectively, while multiple regression analysis revealed
no consistent, statistically relevant influence of age and
baseline tumor size on percent change in tumor size.
Over the course of treatment, there was a demonstrable
overall downward shift in tumor stages from an initial T2-
T4b range to T1a-T2 at Individual End of letrozole treat-
ment. As regards subsequent breast-conserving surgery in
our study, neoadjuvant letrozole treatment enabled
lumpectomy to be performed in 10/14 (71.4%) ITT and
10/14 (71.4%) PP patients after 4 months' treatment and
in 12/15 (80.0%) ITT and 8/11 (72.7%) PP patients
treated for more than 4 months. This underlines the ben-
eficial effect of neoadjuvant letrozole treatment for 4
months or longer.
The observed adverse events considered to be related to
the study medication were not unexpected and mostly
mild to moderate in severity. Two severe adverse events
were classified as unrelated to the study drug. There were
no deaths during the study period, and no dose adjust-
ment or interruption of letrozole treatment was necessary.
Hence, letrozole was generally very well tolerated and
proved safe in this study.
As far as comparison is possible, our data appear to be in
general agreement with findings so far available only as an
abstract by Renshaw and coworkers [20], who carried out
a prospective audit to assess response to 3–12 months'
neoadjuvant treatment with letrozole 2.5 mg/day in 142
postmenopausal women with large operable or locally
advanced ER-rich (Allred score ≥ 6) breast cancer. The
investigators concluded that neoadjuvant letrozole pro-
duced ongoing tumor shrinkage over periods up to 12
months in patients responding to letrozole at 3 Months,
but that there was no optimum duration for the use of
neoadjuvant letrozole.
Conclusion
Based on our findings we draw the overall conclusion that
neoadjuvant letrozole treatment renders more than half
of postmenopausal ER+/PgR+ mastectomy candidates eli-
gible for lumpectomy within only 4 months and that pro-
longed treatment for up to 8 months can result in further
tumor volume reduction and, thus, provide incremental
benefit to patients. Our exploratory data do not suggest
that there is an optimum duration for the preoperative use
of letrozole. However, our study confirms that letrozole
possesses a very favorable toxicity profile and can be safely
and effectively used for at least 8 months in the neoadju-
vant setting.
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